CDX2 and neoplasm: Expression levels from the rest of the evaluated tumor-associated markers (CK17, CK20, MUC5AC, MUC6, CDX2, CEA, CA125, CD10, claudin-4, and villin) showed more variable behavior, ranging from 81.8% (MUC5AC) to 15.4% (CK20) of positivity.